Literature DB >> 9182872

Isolation of anti-mesothelin antibodies from a phage display library.

P S Chowdhury1, K Chang, I Pastan.   

Abstract

Phage display has been used to select single-chain Fvs (scFvs) against mesothelin, a surface antigen present on mesothelial cells as well as mesotheliomas and non-mucinous ovarian cancers. Several attempts to produce anti-mesothelin hybridomas from spleen cells of mice immunized with recombinant mesothelin were unsuccessful. This report describes the isolation of anti-mesothelin scFvs from a phage display library made from the mRNA of the same spleens. Panning on recombinant antigen produced in E. coli or on antigen positive cells was employed. Several scFvs which bind specifically to mesothelin were isolated. Panning on recombinant antigen yielded five different scFvs. Panning on cells selected two different scFvs which also differ from the scFvs selected by recombinant antigen. The heavy chains of the scFvs selected on recombinant antigen are derived from four different heavy chain gene families and the scFvs selected on cells are derived from two of these families. In contrast, the light chains of all of these scFvs are derived from family XI. Moreover, the light chains of the two scFvs selected on cells are very similar to the light chains of two of the scFvs selected by panning on recombinant mesothelin except for a few point mutations. One of these scFvs which have been studied in detail has been shown to bind specifically to mesothelin positive transfected cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182872     DOI: 10.1016/s0161-5890(97)00011-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

Authors:  P S Chowdhury; J L Viner; R Beers; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

3.  Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Authors:  Robert J Kreitman; Raffit Hassan; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

4.  Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Authors:  Dimitra Sasaroli; George Coukos; Nathalie Scholler
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

Review 5.  Immunogenicity of therapeutic recombinant immunotoxins.

Authors:  Ronit Mazor; Masanori Onda; Ira Pastan
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 10.983

6.  Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.

Authors:  Ronit Mazor; Masanori Onda; Dong Park; Selamawit Addissie; Laiman Xiang; Jingli Zhang; Raffit Hassan; Ira Pastan
Journal:  Oncotarget       Date:  2016-05-24

Review 7.  Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin.

Authors:  Seyed Mehdi Havaei; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.